The 11-member committee voted nearly unanimously in November that Biogen's drug should not be approved, citing inconclusive evidence.
Two members of a panel of outside advisors to the U.S. Food and Drug Administration have resigned in protest at theBiogen Inc's Aduhelm for treatment of Alzheimer's disease despite the committee’s recommendation against doing so.
"I was very disappointed at how the advisory committee input was treated by the FDA," Dr. Knopman told Reuters."I don't wish to be put in a position like this again.”
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Two doctors have resigned from a prestigious panel after FDA approved a controversial Alzheimer's drugBusiness Insider tells the global tech, finance, markets, media, healthcare, and strategy stories you want to know.
Read more »
Two members of U.S. FDA advisory panel resign over Alzheimer's drug approvalTwo members of a panel of outside advisors to the U.S. Food and Drug Administration have resigned in protest at the agency's decision to approve Biogen Inc's (BIIB.O) Aduhelm for treatment of Alzheimer's disease despite the committee’s recommendation against doing so.
Read more »
FDA Approval of New Alzheimer’s Drug May Boost Prospects of Other TreatmentsThe Food and Drug Administration’s approval of Biogen's Aduhelm on Monday may have boosted the prospects of other experimental Alzheimer’s disease drugs that target the disease in a similar way
Read more »
Moderna asks FDA to clear Covid vaccine for adolescents 12 to 17If approved, it would likely dramatically expand the number of Covid vaccine shots available to middle and high school students ahead of the next school year.
Read more »
Moderna Asks FDA For Emergency Approval Of Its Covid-19 Vaccine In Teens Aged 12-17Moderna announced that it has filed a request with the FDA for Emergency Use Authorization of its Covid-19 vaccine in teens aged 12-17
Read more »